Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges –

- Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy -

Read more at globenewswire.com